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Quinones are electron and proton carriers that play a primary role in the aerobic metabolism of virtually every cell
in nature. Most physiological quinones are benzoquinones. They undergo highly regulated redox reactions in the
mitochondria, Golgi apparatus, plasma membrane and endoplasmic reticulum. Important consequences of these
electron transfer reactions are the production of and protection against reactive oxygen species (ROS). Quinones
have been extensively studied for both their cytotoxic as well as cellular protective properties and they have been
particularly useful in rational drug design. The role of quinones in medicine is explored in this literature review with
a particular focus on renal diseases. Due to their high basal metabolism and detoxification role, the kidneys are
particularly sensitive to oxidative stress. Regardless of the underlying etiology, ROS plays an important role in both
acute kidney injury (AKI) and chronic kidney diseases (CKD). Depending on the oxidative state of the kidney,
quinones can be nephrotoxoic or nephro-protective. Many factors play a role in the interaction between quinones
and the kidney and the consequences of this are just beginning to be explored.
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Benzoquinones are a class of small molecules that con-
tain two carbonyl groups on a benzene ring. They are
ubiquitous in nature and constitute an important class
of naturally occurring compounds found in plants, fungi
and bacteria. As shown in Figure 1, benzoquinones have
three oxygenation states, fully oxidized, free radical
semi-quinone and fully reduced quinol. In addition, each
of these states can accept up to two protons giving rise
to a total of nine unique redox states (Rich & Bendall
1979). Their unique stability, chemical diversity and
conjugated structure make them ideal biological electron
transfer mediators.
Ubiquinones (co-enzymes Q) are found in the cells of all
aerobic organisms from the simplest bacteria to humans.
They mediate important proton and electron transfer reac-
tions in the mitochondria, chloroplasts, Golgi apparatus,
endoplasmic reticulum and the plasma membrane of oxida-
tive bacteria. Thus they are of key importance in producing
energy during oxidative metabolism and photosynthesis.* Correspondence: jmadeo@numc.edu
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in any medium, provided the original work is pThe electrons are ultimately used to reduce molecular oxy-
gen to water releasing the energy necessary to sustain the
life of the cell. Disruption of this process can lead to disease
states. NADH:ubiquinone oxidoreductase (Complex 1), the
largest multi-meric enzyme complex of the mitochondrial
respiratory chain, is a well-studied example involved in
many disease states including cancer (Albracht et al. 2011).
Dysfunction of this complex is the most common oxidative
phosphorylation disorder in humans (Mimaki et al. 1817).
Leigh syndrome, a subacute necrotizing encephalomy-
elopathy is a well-known example of this (Leigh 1951).
Redox reactions mediated by benzoquinones are the source
of potentially cytotoxic reactive oxygen species (ROS) in-
cluding superoxide, hydrogen peroxide, and the hydroxyl
radical. Quinone mediated ROS can cause cellular damage
through alkylation reactions with lipids, proteins, and DNA
(Bolton et al. 2000). Depending on the particular system,
quinones can act as anti-oxidants and protect healthy cells
against ROS, or act as cytotoxic agents, generating ROS in
unhealthy cancer cells. The generation of ROS and its
cytotoxic effects depend on the inducing chemical, the host
tissue, and other factors that likely influence the electro-
chemical environment. This has been observed with thean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Quinones can accept 2 protons and 2 electrons giving rise to 9 redox states. This chemical diversity has been exploited in nearly
all biological systems. B) Structure of ubiquinone (co-enzyme Q), the most ubiquitous quinone in nature. The long hydrophobic tail allows it to
bind to membranes and proteins and the conjugated ring structure stabilizes electrons, making it the ideal electron transfer molecule.
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the literature revealed that an inflammatory response and
an increased production of ROS are common immune re-
sponses to nanomaterial use which has implications for
drug delivery systems (Syed et al. 2012). On the other hand,
thin walled carbon nanotubes do not appear to produce
cellular damage despite the fact that they produce ROS
(Thurnherr et al. 2011; Ogasawara et al. 2012).
Quinones are of interest from a medical and toxico-
logical prespective due to their unique reactivity and
high prevalence in the environment (Ralph et al. 2011;
Monks & Jones 2002). They undergo highly regulated
redox reactions while bound to specific sites in integral
membrane proteins such as the cytochrome b6f (Kurisu
et al. 2003), QFR (QP,QD) (Iverson et al. 2001), succinate
dehydrogenase (Yankovskaya et al. 2003), DsbB (Zhou
et al. 2008) cytochrome bc1 oxidoreductase (Gao et al.
2003) and photosynthetic reaction centers (Stowell et al.
1997). One extensively studied system that has signifi-
cantly increased our understanding the role of quinone
electrochemistry in biology is bacterial reaction centers
(Gunner et al. 2008). Reaction centers (RCs) are large
membrane-bound proteins that use the energy of a
photon to catalyze a series of electron transfer reactions
during the process of photosynthesis. Ubiquinone-10
simultaneously binds to 2 unique active sites and the
protein mediates electron transfer between them
(Stowell et al. 1997; Zhu & Gunner 2005). This inevit-
ably produces protein-bound free radicals that must be
properly sequestered to avoid cytotoxic damage (Madeo
& Gunner 2005). Studying this system has provided
much insight how proteins have evolved to shift the en-
ergy of electron transfer reactions to fit the needs of the
cell (Madeo et al. 2011).
Quinones in medicine
Quinones play an important role in medicine. Oxidative
stress occurs when there is an imbalance between theproduction and quenching of free radicals from oxygen
species. The mitochondria play a central role in the
formation of excess ROS. Quinones can target the mito-
chondria and re-establish electron transfer in deficiency
states. For example, in antiphospholipid syndrome, treat-
ment with co-enzyme Q has been shown been shown to
alter mitochondrial dynamics resulting in lower oxida-
tive stress and slowing of the accelerated atherosclerosis
(Perez-Sanchez et al. 2012). Co-enzyme Q has also been
shown to prevent retinal cell apoptosis when given as
eye drops in mouse models of kainate-induced retinal
damage (Lulli et al. 2012). Quinones are also being
investigated for the treatment of mitochondrial diseases
(Enns et al. 2012) as well as age-related diseases
(Skulachev et al. 2009). In one small open-label study,
patients with terminal genetic mitochondrial diseases
were treated with a para-benzoquinone (alpha-trocotrienol
quinone) for 13 weeks as an emergency treatment protocol.
This therapy modified disease progression in 90% of the
patients by increasing quality of life and improving central
nervous system oxidation state (Enns et al. 2012). This
quinone is currently undergoing clinical trials for diseases
such as Friedreich’s ataxia, Leigh Syndrome, and Tourette
syndrome.
Depending on their redox state, quinones can act as
both pro and anti-oxidants and their action in the mito-
chondrial is highly dependent on their concentration.
Ubiquinone-10, a fat soluble quinone, is found in par-
ticularly high concentrations in the mitochondria of cells
in the brain, heart, liver, and kidney. Deficiencies in
ubiquinone-10 have been associated with the pathology
of a diverse number of diseases, including encephalop-
athy, myopathy, male infertility, and nephrotic syndrome
(Villalba et al. 2010; Quinzii & Hirano 2010; Balercia
et al. 2009). Accelerated arteriosclerosis is driven by the
proinflammatory response and ubiquinones in the
plasma appear to play a protective role against coronary
artery disease. Co-enzyme Q, by interfering with the
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cluding LDL from oxidation thereby slowing the pro-
gress of coronary artery disease (Morre & Morre 2011;
Tsai et al. 2011). During arteriosclerosis, oxidized LDL
binds to an endothelial cell receptor triggering a signal
transduction pathway that activates NADPH oxidase
resulting in the generation of ROS. The oxidative insult
to the endothelium plays a key role in the pathogenesis of
arteriosclerosis. This pathway was interrupted in endothe-
lial cells pretreated with co-enzyme Q diminishing endo-
thelial oxidative damage (Tsai et al. 2011). Any systemic
inflammatory disease has the potential to cause oxidative
damage due to the increase in aerobic metabolism and thus
could benefit from these protective effects. An important
example is in systemic lupus erythematosus where acceler-
ated atherosclerosis plays an important role (Kurien &
Scofield 2008; Frieri 2012).
NAD(P)H:quinone oxidoreductase 1 (NQO1) is an en-
zyme important in maintaining oxygen homeostasis. It is
a flavoprotein that catalyzes the reduction of quinones,
vitamin E, and nitrogen oxides. These reduction reac-
tions generate natural antioxidants (such as reduced
form of vitamin E and ubiquinol) and are important for
both intrinsic and exogenous chemical detoxification
(Ross et al. 2000). Such reactions can protect against ex-
ogenous quinones that would otherwise promote the
generation of ROS. On the other hand, depending on
the specific initial quinone, these reduction reactions
can generate labile products that react with molecular
oxygen to generate ROS and cause DNA and protein al-
kylation that can thus destroy the cell. This is the
principle behind NQO1 anti-tumor drugs. Compounds
of the quinone family such as mitomycin C are effi-
ciently bioactivated by NQO1, a cytosolic two-electron
reductase. This enzyme activates anti-tumor pro-drugs
and is thus a necessary agent for their anti-tumor activ-
ity (Begleiter et al. 1997). Due to the fact that NQO1 is
expressed in particularly high levels in tumor cells, these
drugs target cancerous cells before becoming toxic to
normal cells. Drugs that target succinate: quinone reduc-
tase/Complex II, another enzyme found in particularly
high levels in tumor cells, is also being developed based
on this principle (Ralph et al. 2006).
Dysregulated ROS production can be cytotoxic, par-
ticularly to cancer cells that have a high metabolism.
Cancer cells are particularly sensitive to insults in redox
homeostasis. ROS production can activate genes in-
volved in detoxification and regulated cell death
(Dhakshinamoorthy et al. 2000). Many cancer cells
maintain a moderate level of oxidative stress and
current investigations are aiming at exploiting this
for targeted cell death (McCarty et al. 2010). Quinones,
due to their redox cycling ability, are being used to exploit
this process and thus represent a large class of antitumordrugs currently under investigation (Siegel et al. 2012; Sagar
et al. 2010). These drugs particularly target cancer cells ra-
ther than healthy cells. The mechanism of death appears to
involve ATP depletion, calcium imbalance, and protein
degradation (Verrax et al. 2011). The reduction of quinones
by NQO1 plays an important role. There is still a lot of
research that needs to be done to understand the role anti-
oxidants play in signal transduction and altering gene
expression. The better we can understand these mecha-
nisms the better we can design specific drugs that target
specific cancers. For example, NQO1 triggers a NF-ĸB me-
diated signal transduction pathway that regulates apoptosis;
NF-ĸB is an important transcription factor in the pathogen-
esis of many cancers, including breast cancer (Zubair &
Frieri 2012). One study showed that expression of NQO1
and NF-ĸB were inversely related in breast tissue implicat-
ing a unique pathway that can be targeted for rational drug
design (Jamshidi et al. 2012).
Due to their anti-oxidant effects, quinones are also
currently being investigated as part of the treatment of
head trauma (Kalayci et al. 2011) and neurological dis-
eases like Parkinson disease (Kerr 2010; Rakoczi et al.
2009), Huntington disease, (Hyson et al. 2010) and
Alzheimer disease (Yang et al. 2010). On the other hand
quinones are involved in the induction of cancer and
neurodegenerative disease (Zahid et al. 2010; Cavalieri &
Rogan 2006). Quinone derivatives of estrogens, benzene,
and dopamine have been showed to promote formation
of DNA adducts that initiate mutations leading to cancer
as well as neurodegenerative diseases (Zahid et al. 2010).
Plastoquinol, an anti-oxidant found in chloroplasts, is
being investigated for its involvement in the suppression
of age-related pathologies such as declining immunity,
balding, cataracts and osteoporosis (Skulachev et al.
2011). Aging is associated oxidative stress, thus quinones
have a potential role in modulating the process (Soares
et al. 2011). Lastly, quinones are still being investigated
for their antimalarial effect (Qu et al. 2010; Jacquerioz &
Croft 2009).
Pathogenesis of renal disease
Hypoxia and cellular reactions to oxidative stress are at
the heart of the complex pathogenesis of both acute and
chronic kidney diseases (Nangaku 2006; Aksu et al.
2011). Acute kidney injury (AKI) affects millions of
people and has been associated with increased mortality
and hospital length of stay as well as puts the patient at
risk for future chronic kidney disease (CKD) (Singbartl
& Kellum 2012). Regardless of the etiology, the path-
ology of AKI is intimately tied to renal microcirculation
and mitochondrial dysfunction resulting in disruption of
oxygen homeostasis, uncontrolled inflammation, and
production of ROS (Kunzendorf et al. 2010). ROS can
promote cell death by both necrosis and apoptosis. ROS
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(Eltzschig & Eckle 2011), antibiotics such as ami-
noglycosides (Ali et al. 2011), contrast induced renal in-
jury (Oudemans-van Straaten 2005), rhabdomyolysis
(Boutaud & Roberts 2011) and toxic materials (Gobe &
Crane 2010; Chen et al. 2011). Therapeutic interventions
aimed at inhibiting these pathological redox reactions is
an active area of current research. NAD(P)H:quinone
oxidoreductase is a redox enzyme found in particularly
high levels in renal tubular cells and likely contributes to
pathogenesis of renal failure. Renal specific oxidases are
known to be involved in ROS medicated damage in
kidney mesangial cells (Orient et al. 2007). Natural
anti-oxidant agents have shown some promise in ameli-
orating aminoglycoside toxicity (Ali et al. 2011; Sayed-
Ahmed & Nagi 2007) and cisplatin-induced nephropathy
(Mukhopadhyay et al. 2012). The role of antioxidants in
the management of AKI is an ongoing area of research
(Koyner et al. 2008).
Oxidative stress is known to play an important role in
the development of renal diseases such as glomeruloneph-
ritis, drug-induced nephrotoxicity, and CKD (Okamura &
Himmelfarb 2009). CKD is associated with mitochondrial
dysfunction that leads to an imbalance between ROS and
the natural anti-oxidants that normally quench these patho-
logical free radicals. In particular hypertensive nephropathy
and proteinuria have been directly linked to salt-induced
oxidative stress (Nagase et al. 2007; Varagic et al. 2010).
One study showed that high salt intake activates the renin-
angiotensin system, urinary protein excretion and
nitroxidative markers in rat models (Varagic et al. 2010). By
using a novel beta-blocker with anti-oxidant function, this
study showed that the kidney damage associated with the
oxidative stress is independent of the hemodynamic dam-
age of hypertension induced by the high salt diet. Salt load-
ing increases activity of plasma membrane NADPH oxidase
in the renal parenchyma, an enzyme important for produc-
tion of ROS (Kitiyakara et al. 2003). Oxidation of LDL by
mesangial cells is important in the pathogenesis of lipopro-
tein glomerulopathy which can lead to rapid progressive
renal failure (Sakatsume et al. 2001). ROS production also
appears to play a key role in diabetic nephropathy and
could be induced by long-standing hyperglycemia (Forbes
et al. 2008). Angiotensin II facilitates ROS production in
kidney mesangial cells which helps to explain the
renoprotective role of ACE-inhibitors and angiotensin re-
ceptor blockers in these disorders (Gorin et al. 2004). An-
other interesting role of anti-oxidants in renal disease is
aristolochic acid 1 (AA1) nephropathy. This disease is asso-
ciated with tubulointerstitial fibrosis and urothelial carcin-
oma following ingestion of AA1 (De Broe 2012). Renal
reduction, which is important for AA1 clearance, generates
a toxic metabolite. One study showed that pre-treatment of
mouse tubular epithelium with a NQO1 inhibitor increasedthe oxidized metabolite of AA1 in renal tissue leading to at-
tenuation of AA1 induced nephropathy (Chen et al. 2011).
This highlights the importance of this enzyme in regulating
renal oxidation and homeostasis and illustrates how genetic
polymorphisms can contribute to a person’s susceptibility
to this disease.
Quinones in renal disease
Quinones can be toxic or protective to the kidneys. The
difference depends on the products produced by reduc-
tion and the oxidative state of the kidney. Stable fully
oxidized quinones are less reactive and their production
can quench other cellular toxins such as ROS. On the
other hand, partially reduced semiquinones are free radi-
cals that can damage DNA and lead to cell death (see
Figure 1). Thymoquinone (TQ), a compound derived
from Nigella sativa, shows strong anti-oxidant properties
against gentamicin (GM)-induced nephrotoxicity. In a
study using a rat model with GM-induced nephrotox-
icity, TQ supplementation lowered BUN, creatinine and
total nitrate/nitrite. It also increased glutathione perox-
idase activity and ATP to match control values. TQ
supplementation also prevented GM-induced renal
histopathology. Based on these findings, the mechanism
of TQ prevention is likely related to its ability to de-
crease oxidative stress by preserving the activity of the
anti-oxidant enzymes (Sayed-Ahmed & Nagi 2007).
With evidence for a similar anti-oxidant mechanism, TQ
also protects the kidney from vancomycin and cisplatin
(Ragheb et al. 2009; Basarslan et al. 2012). Due to its
anti-inflammatory, anti-allergic, and anti-carcinogenic
effects, TQ has been used in traditional medicine for a
diversity of diseases such as cancer, diabetes, and asthma
(Khan et al. 2011; Sankaranarayanan & Pari 2011). One
study observed that TQ reduced sepsis related morbidity
and mortality in mice challenged with endotoxin Gram-
negative bacteria. TQ reduced mortality by 80-90%, im-
proved both kidney and liver function and it also
lowered inflammatory biomarkers (Alkharfy et al. 2011).
Hemodialysis (HD) and peritoneal dialysis (PD) are as-
sociated with increased oxidative stress which may be
related to low levels of co-enzyme Q in the blood. The
major risk of this oxidative stress is accelerated cardio-
vascular disease, the leading cause of death in dialysis
patients. One observational study, comparing dialysis pa-
tients to healthy controls, found an association between
lower co-enzyme blood levels and higher oxidative stress
in dialysis patients (Mehmetoglu et al. 2012). This has
not been a consistent finding and larger, higher powered
studies are needed before this relationship can be ac-
cepted (Gokbel et al. 2011; Lippa et al. 1994). Another
small study followed 36 HD patients for 6 months and
showed that co-enzyme Q10 administration was partially
effective for suppressing the oxidative stress in HD
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examined the benefits and harms of giving antioxidants
to CKD, dialysis, and kidney transplant patients (Jun
et al. 2012). Although the analysis did not detect a
significant decrease in cardiovascular and all-cause
death, there was evidence that antioxidant therapy sig-
nificantly reduced development of end-stage of kidney
disease in CKD patients and lowered serum creatinine
levels. Significant adverse effects were not observed. The
findings of these observational studies have led to the
currently ongoing clinical trial assessing the effect of co-
enzyme Q-10 on oxidative stress and systemic inflamma-
tion in HD patients and have encouraged larger,
appropriately powered studies. Another renal protective
role for quinones has been observed with cold-storage
injury, which occurs with deceased donor kidneys that
are stored at cold temperatures prior to transplantation.
Oxidative damage, from mitochondrial superoxide
generation, plays a role in the tissue injury that occurs
during storage and re-warming (Mitchell et al. 2010).
Mitoquinone is a ubiquinone analog with a conjugated
hydrophobic anion that targets the mitochondria and
has been shown to protect against cold storage damage
of renal tubular cells by preventing mitochondrial
dysfunction (Mitchell et al. 2011).
The toxicity of quinones to the kidney appears to de-
pend on a variety of factors including genetic polymor-
phisms and the disease state of the individual. NQO1 is
found, in particular high levels in podocytes indicating
that these cells play a pivotal role in the oxidative state
of the kidney (Tamura et al. 2012; Marshall et al. 2006).
The likely role is a detoxifying enzyme, protecting the
kidney from chemically reactive metabolites filtered
through the glomerulus. Mitomycin C is an anticancer
agent that is particularly toxic to the kidney and known
to cause hemolytic uremic syndrome (Zappa et al. 2003).
It is a quinone that requires cellular reduction to activate
its cytotoxic effects. Due to its ability to reduce qui-
nones, NQO1 in podocytes could play a major role in
the pathogenesis of renal toxicity and mitomycin C-
induced hemolytic uremic syndrome. Injury to the
glomerular filtration mechanism is the primary damage,
leading to a cascade of deleterious events including
microangiopathic hemolytic anemia and thrombocytopenia
(Zappa et al. 2003). The high expression of NQO1 explains,
in theory, a selective toxicity towards podocytes. Another
mechanism may be the formation of covalent protein
quinol-thioether adducts. Glutathione (GSH) conjugates of
hydroquinone (HQ) and 2-bromohydroquinone (2-BrHQ)
produce severe renal proximal tubular necrosis in rats
(Kleiner et al. 1998).
Podocytes are the major cell of the glomerular filter.
They are highly differentiated and quiescent cells in-
volved in the pathology of numerous kidney diseases(Durvasula & Shankland 2006; Garg & Holzman 2012).
The glomerular filtrate must traverse capillary endothe-
lium, basement membrane, and the podocyte layer be-
fore reaching Bowman’s space. Podocytes also produce
vascular endothelial growth factor (VEGF), which regu-
lates glomerular endothelial permeability, thus playing
an important role in the kidney interactions with poten-
tial toxins (Kretzler et al. 1998). Expression of VEGF has
been shown to be important in many renal diseases, par-
ticularly lupus nephritis (Frieri et al. 2012). An acquired
primary dysregulation of podocytes is described in col-
lapsing idiopathic focal segmental glomerulosclerosis
and in HIV-associated nephropathy (Barisoni et al.
1999), another disease driven by unregulated oxidative
stress.
Primary coenzyme Q10 deficiency is considered to be
the only treatable mitochondrial disorder, since some
patients have a response to oral coenzyme Q-10 (Salviati
et al. 2005). The disease usually manifests with nephrop-
athy and encephalomyopathy (Montini et al. 2008). It is
caused by mutations in the enzymes of the coenzyme
Q10 synthetic pathway. It has been linked with focal
segmental glomerulosclerosis due to dysfunctional mito-
chondria in the podocytes. One study using a transla-
tional mouse model showed that giving probucol (a lipid
soluble anti-oxidant) prevented an otherwise lethal
glomerulopathy (Falk et al. 2011). This drug resulted in
higher levels of co-enzyme Q in kidney and liver com-
pared to supplementation alone. The benefit appears to
be due to effects on signaling pathways that alter gene
expression resulting in reduction of oxidative stress.
Since not all patients with co-enzyme Q deficiency re-
spond to supplementation, alternative therapies targeting
the signaling pathways that mediate oxidative stress are
needed.
Another study described the effects of long-term coen-
zyme Q10 supplementation in a patient with coenzyme
Q10 deficiency (Diomedi-Camassei et al. 2007). Progres-
sive recovery of renal function and resolution of neph-
ritic syndrome were observed during the 50 months of
treatment. Corticosteroids and immunosuppressive
drugs were not needed. On the other hand, a second
patient was treated with co-enzyme Q after the develop-
ment of CKD and no change in renal function was
observed. Thus, early administration of coenzyme Q10
appears to be important for the resolution of renal
symptoms.
Conclusions
This literature review highlights the relationship between
benzoquinones, oxidative stress, and renal disease. Qui-
nones are small electron transfer molecules, found in
virtually all cells that undergo aerobic metabolism, that
play an important role in oxidative stress. Quinones have
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and anti-aging and arteriosclerosis. Quinones can be
renal toxic or renal protective. Thymoquinone protects
the kidney from toxic effects of drugs, including genta-
micin, vancomycin and cisplantin. Mitoquinone can pro-
tect against cold storage damage of deceased donor
kidneys. Mitomycin C is an anticancer agent that is par-
ticularly toxic to renal podocytes because it targets the
detoxifying enzyme NQO1. Primary coenzyme Q10 defi-
ciency also results in kidney damage primarily due to
dysfunctional mitochondria in the podocytes. CoQ10 ad-
ministration was partially effective for suppressing the
oxidative stress in dialysis patients. Although the role of
co-enzyme Q in CKD and ESRD is not fully established,
encouraging observational studies and lack of significant
adverse effects encourage future investigations. Many
factors play a role in the interaction between quinones,
oxidative stress and kidney physiology. Future studies,
including clinical trials, can help to better unravel this
role and improve the management of patients with or at
risk for kidney diseases.
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